ReCode Therapeutics

Let’s talk about cystic fibrosis (CF) - a progressive, fatal genetic disease that, if left untreated, can cause persistent lung infections and respiratory failure. What else do you need to know? Swipe to learn more. What’s something you’d like to bring to light about CF? #CysticFibrosis #GeneticMedicine #mRNA

Clinical Study News: ReCode is currently recruiting for a clinical study in the UK for people with PCD. For more information about this clinical study, visit https://lnkd.in/gupUm-8U In January, the first patient was dosed in our Phase 1 clinical study of RCT1100, a novel mRNA-based medicine for patients with primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations. By giving DNAI1-mRNA as a therapy to people with PCD caused by this missing protein, it may be possible to restore ciliary function in the lungs, addressing the underlying cause of PCD rather than just controlling the symptoms of the disease. In a Phase 1 single-dose study, RCT1100 was well tolerated by healthy individuals and a small number of people with PCD with disease-causing mutations in DNAI1. #PCD #GeneticMedicines #PatientsFirst #PrimaryCiliaryDyskinesia

We’re thrilled to announce that the Cystic Fibrosis Foundation has agreed to invest up to $15 million in additional funding to accelerate our gene correction research program, developed in collaboration with Intellia Therapeutics, Inc. This support advances our work, combining our innovative SORT LNP delivery platform with Intellia’s cutting-edge CRISPR DNA-writing technology. This funding will help develop up to three unique gene correction programs, bringing hope for transformative new therapies. Together, we’re tackling the root genetic cause of cystic fibrosis (CF), initially focusing on mutations current treatments cannot adequately address. We’re proud to continue our partnership with the CF Foundation, building on their support of our inhaled mRNA therapy, RCT2100, which is now in a Phase 1b trial. Together, we are working to create new therapeutic solutions for everyone affected by this genetic disease and ensure no one is left behind. Read the full release here: https://bit.ly/48V3PPi #CysticFibrosis #Biotech #ReCode #GeneticMedicine #CRISPR

John Matthews, our Chief Medical Officer, speaks on the state of our cystic fibrosis research pipeline: "RCT2100, our inhaled CFTR mRNA therapy, is optimized to reach the correct cells in the lungs and instruct them to make a functional version of the CFTR protein. This would represent an exciting step in developing a successful therapy for all CF patients.” This development addresses a critical gap in #CF treatment, particularly for Class I #CFTR mutations where no protein is produced. #CysticFibrosis #InnovationInHealthcare #ReCodeTherapeutics

This Veterans Day, we recognize the courage, dedication, and sacrifices of the brave individuals who’ve served our nation. Your commitment has protected our freedoms and shaped the values we hold dear. From all of us at ReCode, we extend our deepest gratitude to veterans everywhere—thank you for your service and strength.

Did you know it’s estimated that over 50,000 people have undiagnosed primary ciliary dyskinesia (PCD)? This rare genetic disorder often goes unnoticed until adulthood, leading to a decline in lung function without early intervention. The diagnosis process can be complex and challenging - which is why raising awareness of PDC is critical. For more information about a clinical study for a potential new treatment for PCD, recruiting in the UK, and the risks involved, visit https://lnkd.in/gupUm-8U #PCD #GeneticMedicines #PatientsFirst #PrimaryCiliaryDyskinesia

Ariel Kantor, PhD, our SVP of Business and Corporate Development, will be a featured panelist in the “Investor Perspectives” discussion at next week's AMM ASCENT conference in Boston. Dr. Kantor recently shared his insights on the future of mRNA therapeutics at TIDES USA 2024, where he presented ReCode’s Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform for Lung Delivery on the Plenary Panel Discussion: "mRNA Therapies – The Next Chapter.” TIDES Global?recently spoke with Kantor, who is a 2023 recipient of the Forbes 30 Under 30 for Science and Healthcare, and a Rhodes Scholar.?Learn more about Ariel and his perspectives on the next chapter of mRNA therapies?here:?https://lnkd.in/eS8SwYff

At ReCode Therapeutics, we're reshaping the future of Cystic Fibrosis (CF) treatment with our SORT LNP platform. Our clinical-stage candidate, RCT2100, targets the root cause of CF, particularly for the 10-13% of patients with Class I CFTR gene mutations who don't benefit from current treatments. This inhaled therapy is designed to deliver CFTR mRNA directly to target cells, enabling the production of functional CFTR protein, and offering new hope to a broader range of CF patients. Learn more at https://lnkd.in/gx-T4xR4 #CysticFibrosis #CF #GeneticMedicine

This Native American Heritage Month, we at ReCode Therapeutics celebrate the diverse cultures, traditions, and contributions of Native American communities. It’s also an important time to reflect on the healthcare challenges these communities face, and to consider how we can contribute to building a more inclusive and equitable healthcare system. Our commitment at ReCode goes beyond innovation — it’s about ensuring that the benefits of medical advancements reach everyone. By working to diversify representation in clinical trials, we strive to create treatments that serve the needs of all communities, including Native American populations. #NativeAmericanHeritageMonth #EquityInHealthcare #InclusiveInnovation

Our VP of Intellectual Property & Business Development, Eneda Hoxha, will join a panel on "Licensing Deals for Gene Editing Therapeutic & Delivery Technologies" at the 5th Annual Genome Editing Therapeutics Summit, December 3-5 in Boston. We look forward to her sharing insights on advancing IP strategies in genetic medicine innovation.